Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
about
Modelling clinical systemic lupus erythematosus: similarities, differences and success storiesDrugs for discoid lupus erythematosus.Lupus pathobiology based on genomics.Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.Interferon (IFN)-λ is a potential mediator in lupus nephritisDeveloping connections amongst B lymphocytes and deregulated pathways in autoimmunity.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus ErythematosusSubcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Update on cardiovascular disease in lupus.Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.Systemic lupus erythematosus: still a challenge for physicians.NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils.Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.Systemic lupus erythematosus diagnosis and management.It hasn't gone away: the problem of glucocorticoid use in lupus remains.Synthetic pharmacotherapy for lupus nephritis.Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Novel Treatments in Lupus.Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.Regulating STING in health and diseaseMass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients.The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.IRF3 and type I interferons fuel a fatal response to myocardial infarction.Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.Cytokine and autoantibody clusters interaction in systemic lupus erythematosus.Potential role of type I interferon in the pathogenic process leading to type 1 diabetes.Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?An era of biological treatment in systemic lupus erythematosus.New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production.Kallikrein–Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.Diagnostic and prognostic tests in systemic lupus erythematosus.Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study.Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop.
P2860
Q28074217-B38AE9E2-14FA-4E2E-B932-E1CBB7E61807Q30234556-F110B53C-E4E2-4209-AFC2-89312E735E8EQ33364409-2CF367CC-6395-4B73-87BE-D0D0160F9168Q33731705-31742905-5C6B-4DC2-80EB-F98BE5782CE3Q37464013-C90F49EC-31BE-4621-BA57-7FFF987E5B55Q37468684-5E6C5B24-B14B-4548-9F15-028D6E765865Q37633408-13EE7975-09DB-4948-BB92-5613BA4F0032Q38605480-24C0736C-71B7-45C2-B83A-0D9E0D243EA0Q38690844-88EC75F4-694F-4508-BC2B-5B7D23D3910AQ38844782-0AB6D26C-EE2D-4D05-8F0C-401AE53F2EB1Q38850089-A12D4ADE-343B-411E-9245-EEB35BE1D7ABQ38857518-CB6DE658-7995-462A-9A1C-80BAB806E8BBQ38866356-73830377-2793-482C-BB72-EE65F79C2D92Q38998709-249BBB26-3F9E-47A3-B724-87FDF6B8342DQ39045512-C09C88EF-F07F-4D5B-9ED8-EE0095BBC3BCQ39053129-C3E7D00C-4EAD-4E24-BD28-41A9B3572899Q39053147-8C61DB2D-27E6-4D11-B6AC-6B8BD5B7B19FQ39064602-F96BA8A1-591D-467A-BEC8-C244B2A95F91Q39088664-77459C9C-7514-43BF-8ED7-5B7F303D515BQ39122684-9BBE3527-855F-46AF-962D-057C1AF8F3C9Q39150632-4FB8B99B-13AE-4455-9814-2722EAE15AE9Q39164953-A51EAB95-0A31-4578-A084-87384E05E0B8Q39303557-A1AC2E52-F170-4F18-96F6-BA8BB4F8E6FFQ39360861-3C4904BD-5E31-4794-8BE5-673B04E378ABQ40260152-EF3AFF3F-9781-4273-B579-0F3F7C1C5981Q40414181-B603440E-611F-49FC-B690-D8D2B530B086Q41912068-B376D570-32C9-49DE-8909-57A35DD45E57Q41913718-5A747A37-9BD9-4577-A790-F8B9B2FD95ACQ46039774-1216C872-FAF0-459E-B9C7-7A9899C428CCQ46803412-915DD48C-F5D2-4AB3-8D58-E590B380BACBQ47120444-BD58D1AA-2AC2-49DA-BF95-9AC9AE2B8D06Q47548945-DEE9B854-4679-41FA-AE58-9E271544A06EQ47900605-9D47896A-C0AE-4C66-A9E7-C033E2B8B9F8Q48128911-2AF0F70E-F451-4C9A-BCA3-E666C31ABF14Q49499785-D1F703EE-8FBA-40C7-A0A6-C5BBB1368B88Q49852055-156121B4-D6F0-417C-8D46-AD66B697FEF8Q49884872-5F05DB91-2701-46EB-BA1A-E52F09B3AAACQ49966463-E3545681-9CB0-4F99-A966-8366CF5C1FFAQ51324016-D7AF506B-E311-4152-AB62-BA466CBFBED7Q51487509-696EC85C-B914-40DB-8FAD-12892BBE67BB
P2860
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@en
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@nl
type
label
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@en
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@nl
prefLabel
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@en
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@nl
P2093
P2860
P1476
Sifalimumab, an anti-interfero ...... ind, placebo-controlled study.
@en
P2093
CD1067 study investigators
Gabor G Illei
Joan T Merrill
Jorn Drappa
Kenneth Kalunian
Liangwei Wang
Richard Furie
Victoria P Werth
Warren Greth
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-208562
P407
P577
2016-03-23T00:00:00Z